Published TCIMAIL newest issue No.201
Maximum quantity allowed is 999
CAS RN: 475207-59-1 | Product Number: N1229
Sorafenib Tosylate
Purity: >98.0%(T)(HPLC)
- 4-[4-[3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido]phenoxy]-N-methylpicolinamide 4-Methylbenzenesulfonate
- 4-[4-[[4-Chloro-3-(trifluoromethyl)phenyl]carbamamido]phenoxy]-N-methyl-2-pyridinecarboxamide 4-Methylbenzenesulfonate
* Stock available in Belgium: Shipment on the same day
* Stock available in Japan: Please check the Shipping Simulation for estimated shipments. (excludes regulated items and dry ice shipments)
| Product Number | N1229 |
Purity / Analysis Method
|
>98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__2__1H__1__6ClF__3N__4O__3.C__7H__8O__3S = 637.03 |
| Physical State (20 deg.C) | Solid |
Storage Temperature
|
Refrigerated (0-10°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Air Sensitive,Heat Sensitive |
Packaging and Container
|
1G-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 475207-59-1 |
| Reaxys Registry Number | 11116227 |
| MDL Number | MFCD08235032 |
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Neutralization titration) | min. 98.0 % |
| Melting point | 222.0 to 226.0 °C |
| NMR | confirm to structure |
| Melting Point | 224 °C |
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H360 : May damage fertility or the unborn child. H362 : May cause harm to breast-fed children. |
| Precautionary Statements | P263 : Avoid contact during pregnancy and while nursing. P260 : Do not breathe dust. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection/ hearing protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. |
| RTECS# | US4588880 |
| HS Number | 2933399999 |
References
- 1) BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
- 2) Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5
- 3) BAY 43-9006 Inhibition of Oncogenic RET Mutants
- F. Carlomagno, S. Anaganti, T. Guida, G. Salvatore, G. Troncone, S. M. Wilhelm, M. Santoro, J. Natl. Cancer Inst. 2006, 98, 326.

- 4) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer (a review)
- 5) Sorafenib: a review of its use in advanced hepatocellular carcinoma
- 6) Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice
Documents
Safety Data Sheet (SDS)
The requested SDS is not available.
Please Contact Us for more information.
The requested SDS is not available.
Specifications
The requested specifications are not available.
Please Contact Us for more information.
The requested specifications are not available.
C of A & Other Certificates
Please check that the lot number you have entered is correct. It is 4-5 alphanumeric characters before the hyphen. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
If your information is correct and you are still not able to view the requested certificates, Please Contact Us for more information.
Please check that the lot number you have entered is correct. It is 7 alphanumeric characters. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
Sample C of A
A sample C of A for this product is not available at this time.
Analytical Charts
The requested analytical chart is not available. Sorry for the inconvenience.